Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer trial adding radiation to immunotherapy halted early

NCT ID NCT05223647

Disease control Sponsor: Norwegian University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding radiation to the chest could improve survival for people with extensive-stage small-cell lung cancer who were already receiving chemotherapy and immunotherapy. The trial planned to enroll 239 participants but was terminated early. The main goal was to see if the combination increased the number of people alive after one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

239 people

The number who actually took part.

Started

Jan 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 years at time of study entry 2. ECOG performance status of 0 or 1 3. Body weight \>30 kg 4. Adequate bone marrow, liver and kidney function 5. Life expectancy of at least 3 months 6. At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 30 Gy/10 fractions 7. Histologically or cytologically confirmed SCLC 8. Stage III-IV disease (TNM v8) 9. FEV1 \>1 L or \>30 % of predicted value and DLCO \>30 % of predicted value 10. Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and/or anticonvulsants prior to the start of treatment Exclusion Criteria: 1. Previous chemo-, immuno- or radiotherapy for SCLC 2. Major surgical procedure last 28 days 3. History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV 4. Uncontrolled intercurrent illness 5. Other active malignancy 6. Leptomeningeal carcinomatosis 7. Immunosuppressive medication 8. Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung cancer

Contacts and locations

Locations

  • Akershus Universitetssykehus AHUS

    Oslo, Norway

  • Cancer Clinic at St. Olavs Hospital

    Trondheim, Norway

  • Drammen sykehus - Vestre Viken

    Drammen, Norway

  • Erasmus MC

    Rotterdam, Netherlands

  • Gävle hospital

    Gävle, Sweden

  • Haugesund hospital

    Haugesund, Norway

  • Haukeland Universitetssykehus

    Bergen, Norway

  • Innlandet hospital Gjøvik

    Gjøvik, Norway

  • Karolinska University Hospital

    Stockholm, Sweden

  • Landspitali University Hospital

    Reykjavik, Iceland

  • Linköping University Hospital

    Linköping, Sweden

  • Lund University Hospital

    Skåne, Sweden

  • Nordlandssykehuset HF

    Bodø, Norway

  • North Estonia Medical Centre

    Tallinn, Estonia

  • Oslo University Hospital Ullevål

    Oslo, Norway

  • Sahlgrenska Sjukehuset

    Gothenburg, Sweden

  • Stavanger University Hospital

    Stavanger, Norway

  • Sykehuset Levanger

    Levanger, Norway

  • University Hospital of North Norway, Pulmonology Department

    Tromsø, Norway

  • Ålesund Hospital

    Ålesund, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.